After 30 years of listing, employees have something to say.
Release time:
2023-04-21
Hong Zhiwei (Production Department of Jianfeng Pharmaceutical):
I have been working in Jianfeng for nearly 25 years. I have experienced many things, learned a lot, understood a lot and gained a lot. Over the years, my leadership has changed a lot, and my colleagues have changed a lot, but my love for spikes has not changed.
I used to work in Jinhua Biochemical Pharmaceutical Factory. Biochemical pharmaceutical factory products, the benefit is good, but the old plant, the surrounding environment is poor, can not meet the GMP requirements. After being merged and acquired by the peak, the plant has been upgraded and the welfare of employees has also been improved. From then on, I became a spike man.
In 2001 , Qiubin Pharmaceutical Factory started construction and recruited employees throughout the company. After several strict examinations of written examinations and interviews, I entered Qiubin Pharmaceutical Factory. At that time, the Qiubin factory produced injection products such as soft bags, glass bottles and middle needles. Two workshops and four production lines were started at the same time. The machines in the workshop roared, and the employees were working in full swing and all of them were full of energy. Anyone who watched the scene would feel excited.
Qiubin Pharmaceutical Factory has advanced equipment and strict management, with special emphasis on product quality and environmental hygiene. Previously, the workshop was divided into 300,000 levels, 100,000 levels, 10,000 levels and 100 levels. Each process and batch of products produced had standardized operation records for retrospective search. Employees should conduct GMP training, post SOP training, safety training, etc. every once in a while to ensure safe and effective production.
In the packaging post, the old method of manual packaging was initially used. Later, the linkage packaging machine was used instead. From labeling, small box packing, plastic packaging, code scanning, to packing and packing, the whole process of integrated packaging was replaced by linkage machine, thus saving cost and improving efficiency.
The development of the peak is inseparable from the improvement of product quality, and the improvement of product quality is inseparable from the improvement of each employee's awareness of product quality. As a peak person, on the occasion of the 30-year listing of this peak stock, I hope that the future peak will flourish and create more and better products to make our company invincible. I'm a spike man and I'm proud of the spike.
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page